Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01)

0
372

Funding Opportunity ID: 296478
Opportunity Number: RFA-DK-17-509
Opportunity Title: Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
CFDA Number(s): 93.847
Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for full eligibility details.
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Aug 14, 2017
Close Date: Dec 05, 2017
Last Updated Date: Aug 14, 2017
Award Ceiling: $250,000
Award Floor:
Estimated Total Program Funding: $2,140,000
Expected Number of Awards: 6
Description: The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.
Version: Synopsis 1





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here